Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF JULY 20, 2018 FBO #6083
SPECIAL NOTICE

R -- Subject Matter Expert Support for Nonclinical Study Data - NOI1201138

Notice Date
7/18/2018
 
Notice Type
Special Notice
 
NAICS
325413 — In-Vitro Diagnostic Substance Manufacturing
 
Contracting Office
Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services - Rockville, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001, United States
 
ZIP Code
20857-0001
 
Solicitation Number
NOI1200737
 
Point of Contact
Telisha Wilson, Phone: 2404027572
 
E-Mail Address
telisha.wilson@fda.hhs.gov
(telisha.wilson@fda.hhs.gov)
 
Small Business Set-Aside
N/A
 
Description
Cytokine Plates PRESOLICITATION NOTICE: INTENT TO AWARD A SOLE-SOURCE CONTRACT INTENDED SOURCE: Meso Scale Diagnostics, LLC ANTICIPATED PERIOD of PERFORMANCE: Delivery 30 days after award DESCRIPTION OF REQUIREMENT: Pursuant to the authority of 41 USC 3304(a)(1), as implemented by Federal Acquisition Regulation (FAR) Subpart 13.501(a)(1)(ii), the U.S. Food and Drug Administration (FDA), Office of Acquisitions and Grant Services (OAGS) intends to award a sole source contract to Meso Scale Diagnostics, LLC is solo manufacturer of the MiSeq instrument. The Government intends to solicit and negotiate directly with Meso Scale Diagnostics, LLC and no solicitation will be issued. Meso Scale Diagnostics is the only vendor that can provide the custom plate that is required because we are limited by extremely small samples size and require the limit of detection offered by MSD system products. The applicable North American Industry Classification System (NAICS) code for this acquisition 334516, Analytical Laboratory Instrument Manufacturing. This notice of intent is not a request for competitive proposals or quotations; however, if any interested party believes they can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities shall be submitted in writing and shall contain material in sufficient detail to allow the government to determine if the party can perform the requirement. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. All interested parties shall express their interest and capabilities in writing via email to Telisha.Wilson@fda.hhs.gov within fifteen (10) days after the date of publication of this notice. No faxed documents will be accepted. If no responsive statements are received within fifteen (15) days, an award will subsequently be made to Illumina, Inc. This is a Federal contract opportunity; FDA-NOI-1201138 for services at Food and Drug Administration Office of Acquisitions and Grants Services - Rockville, MD. Response Due NLT 10:00 AM 07/13/2018 Solicitation Number FDA-NOI-1201138 Set-Aside No Set-Aside Used Contact(s) Telisha Wilson Agency Department of Health and Human Services Office Food and Drug Administration Location Office of Acquisitions and Grants Services - Rockville
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/NOI1200737/listing.html)
 
Record
SN04996981-W 20180720/180718231011-1d0dc2a5e0f208447d11f093cd484227 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  © 1994-2020, Loren Data Corp.